Charles River Laboratories International, Inc. (CRL)

NYQ – Real vaqt narxi. Valyuta: USD

284.30

+2.30 (0.82%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

286.63

+2.26 (0.79%)

Bozordan keyin: Aug 12, 2026, 4:40 PM EDT

10.08.2026

International Markets and Charles River (CRL): A Deep Dive for Investors

Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

06.08.2026

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

06.08.2026

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.

05.08.2026

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

05.08.2026

CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market

Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.

05.08.2026

Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?

Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.

05.08.2026

Charles River: Near-Term Inflection But Long-Term Risk

Charles River Laboratories has rebounded 40% from last year, driven by improved organic revenue and a positive inflection in order trends. CRL raised guidance, now expecting slightly positive organic growth and EPS of $11.15–$11.45, with margin expansion locked in through divestitures and cost cuts. Segment performance is mixed: DSA shows strong backlog and book-to-bill, while RMS faces U.S. weakness offset by China strength; manufacturing margins benefit from divestitures.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
CRL	JP Morgan	Overweight	undefined >> $310	August 6th 2026

Press-relizlar

05.08.2026

Charles River Laboratories Announces Second-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2026 Financial Results.

Charles River Laboratories International, Inc. (CRL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Charles River Laboratories International, Inc. (CRL)

International Markets and Charles River (CRL): A Deep Dive for Investors

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market

Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?

Charles River: Near-Term Inflection But Long-Term Risk

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Charles River Laboratories Announces Second-Quarter 2026 Results

International Markets and Charles River (CRL): A Deep Dive for Investors

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market

Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?

Charles River: Near-Term Inflection But Long-Term Risk

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Charles River Laboratories Announces Second-Quarter 2026 Results

Search stocks

Charles River Laboratories International, Inc. (CRL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Charles River Laboratories International, Inc. (CRL)

International Markets and Charles River (CRL): A Deep Dive for Investors

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market

Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?

Charles River: Near-Term Inflection But Long-Term Risk

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Charles River Laboratories Announces Second-Quarter 2026 Results

International Markets and Charles River (CRL): A Deep Dive for Investors

This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript

CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market

Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?

Charles River: Near-Term Inflection But Long-Term Risk

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

Charles River Laboratories Announces Second-Quarter 2026 Results